{
  "trial_id": "NCT01092182",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Burkitt Lymphoma",
      "label": "met",
      "evidence": "fluid analysis was consistent with Burkitt's lymphoma"
    },
    {
      "criterion": "Age greater than or equal to 18 years",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Pathology confirmed by treating institution s Pathology Department",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "No prior treatment except patients may be entered if they have had prior limited-field radiotherapy, a short course of glucocorticoids, cyclophosphamide for an urgent problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome) and/or a single dose of intrathecal methotrexate (MTX) at the time of the pre-treatment diagnostic lumbar puncture",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "All disease stages",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "HIV negative or positive",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "ECOG 0-4",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Ability of patient or durable power of attorney (DPA) for healthcare to give informed consent",
      "label": "met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Primary CNS Lymphoma",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Inadequate renal function, defined as serum Cr > 1.5 or creatinine clearance < 50ml/min/1.73m2 unless lymphoma related",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Inadequate hepatic or hematological function: as follows, unless lymphoma-/disease-related: bilirubin greater than 2 mg/dl (total) except greater than 5 mg/dl in patients with Gilbert s syndrome as defined by greater than 80% unconjugated, ANC less than 1000 and platelets less than 75,000",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "The effects of EPOCH-R on the developing human fetus are unknown. For this reason and because chemotherapy agents are known to be teratogenic, female subject of child-bearing potential not willing to use an acceptable method of birth control(i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and one year beyond treatment completion will not be eligible to participate in the study.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Female subject pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for women without child-bearing potential.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "The effects of EPOCH-R on the developing human fetus are unknown. For this reason and because chemotherapy agents are known to be teratogenic, male subject unwilling to use an acceptable method for contraception for the duration of the study and one year beyond treatment completion, will not be eligible to participate in the study.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "History of a prior invasive malignancy in past 5 years.",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "Patient has Burkitt Lymphoma, is over 18 years old, and has no prior treatment except for limited-field radiotherapy. However, patient's renal function is unknown and they may be pregnant or breast-feeding.",
  "_meta": {
    "topic_id": "4",
    "trial_id": "NCT01092182",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}